torcetrapib

Also known as (2R,4S)-4-((3,5-bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.

Research

396 papers

Torcetrapib/atorvastatin combination therapy.Expert review of cardiovascular therapy · 2005
Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies.Bioanalysis · 2009
The end of the road for CETP inhibitors after torcetrapib?Current opinion in cardiology · 2009
The failure of torcetrapib: is there a case for independent preclinical and clinical testing?Expert opinion on pharmacotherapy · 2008
JTT-705: is there still future for a CETP inhibitor after torcetrapib?Expert opinion on investigational drugs · 2008

via PubMed

Wikidata facts

Mass: 600.167

Show 4 more facts

chemical formula: C₂₆H₂₅F₉N₂O₄
canonical SMILES: CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC
isomeric SMILES: CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC
Commons category: Torcetrapib

Sources (2)

via Wikidata · CC0

~6 min read

Article

10 sections

Contents

Medical uses
Mechanism
Development
Clinical trials
Early termination of study
Synthesis
See also
References
Notes
External links

{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461752029 | ImageFile = Torcetrapib.svg | ImageSize = | PIN = Ethyl (2R,4S)-4-({[3,5-bis(trifluoromethyl)phenyl]methyl}(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate | OtherNames =

| Section1 =